trending Market Intelligence /marketintelligence/en/news-insights/trending/04O1Mgz4NrVR3nyLxzn7wA2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

GOP lawmakers hesitant to support ACA repeal; Biogen's MS drug under review

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


GOP lawmakers hesitant to support ACA repeal; Biogen's MS drug under review

* An audit by the U.S. Department of Health and Human Services' Office of Inspector General showed that the Centers for Medicare and Medicaid Services erroneously paid an estimated $729 million to professionals to accelerate the use of electronic health records.

* U.S. Vice President Mike Pence told attendees at a Milwaukee fundraiser that the Trump administration was working to repeal and replace the Affordable Care Act before the end of summer, The Washington Times reported.

* Meanwhile, some Republican lawmakers are hesitant to support a bill to repeal and replace the ACA over worries that it could affect coverage of millions of people on substance-abuse treatment, The Wall Street Journal wrote.

* The Wall Street Journal carries a report on the U.S. investigation of charities that help patients pay for expensive drugs, including prostate cancer drug manufacturers who relied on such charities to boost sales.

M&A and capital markets

* The European Commission gave the final approval needed to complete Johnson & Johnson's acquisition of Actelion Ltd. As part of the transaction, Actelion will spin out its drug discovery operations and early stage clinical development assets into Idorsia Ltd. — a newly created Swiss biopharmaceutical company that will be listed on the SIX Swiss Exchange.

* Swedish biotechnology company Bonesupport priced its IPO on NASDAQ Stockholm at between 27 Swedish kronor and 31 Swedish kronor per share, translating to a market capitalization of 1.36 billion kronor to 1.47 billion kronor, Reuters reported.

Drug and product pipeline

* Merck & Co. Inc. and Pfizer Inc.'s oral investigational drug ertugliflozin met its primary endpoint of improving glycemic control in adults with type 2 diabetes. The drug was being investigated in two phase 3 studies and in combination with metformin or sitagliptin.

* Sanofi and Regeneron Pharmaceuticals Inc.'s Praluent reduced low-density lipoprotein cholesterol and was found to be superior to usual care in reducing non-high-density lipoprotein cholesterol in two separate phase 3b/4 trials.

* The European Medicines Agency is reviewing Biogen Inc.'s multiple sclerosis drug Zinbryta following a patient's death from fulminant liver failure and four cases of serious liver injuries.

* An independent data monitoring committee recommended the early termination of XBiotech Inc.'s phase 3 trial of Xilonix, noting the study's findings were not enough to meet the colorectal cancer treatment's efficacy or the threshold for continuation.

Operational activity

* A federal jury asked AbbVie Inc. to pay $15 million in compensatory damages to Stevie Gonzalez, who was born with spina bifida. Gonzalez's mother alleged that the company's bipolar disorder drug Depakote caused the birth defect in the 10-year-old boy, Reuters reported.

The day ahead

Early morning futures indicators pointed to a lower opening for the U.S. market.

In Asia, the Hang Seng closed 1.24% lower to 25,708.04, while the Nikkei 225 decreased 0.52% to 19,908.58.

In Europe, around midday, the FTSE 100 was down by 0.14% to 7,516.47 and the Euronext 100 0.96% lower at 1,014.05.

The Daily Dose is updated as of 6:30 a.m. ET. Some external links may require a subscription.